Close menu




June 7th, 2021 | 08:32 CEST

CureVac, Cardiol Therapeutics, Formycon, NanoRepro - Pharma stocks with potential!

  • Biotechnology
Photo credits: pixabay.com

In Germany, around 231,000 people died as a result of cancer in 2019. As reported by the Federal Statistical Office, cancer was the cause of a quarter of all deaths. This proportion has hardly changed within 20 years, even though the number of cancer deaths has increased by around 10% since 1999. The precise number 1 cause of widespread disease in Germany is cardiovascular disease, such as heart failure, coronary heart disease and myocardial infarction. With 18.2 million deaths, they represented the most common cause of death worldwide in 2019. In Europe, more than 4 million people die each year due to such a disease, 1.4 million of whom are younger than 75. So research continues to be in demand. We look at interesting representatives of the industry.

time to read: 5 minutes | Author: André Will-Laudien
ISIN: NL0015436031 , CA14161Y2006 , DE000A1EWVY8 , DE0006577109

Table of contents:


    Cardiol Therapeutics - Milestones in cardiac research

    The causes of cardiovascular disease are manifold and can be divided into influenceable and non-influenceable risk factors. The natural parameters include, for example, age, gender and genetic predisposition. The other influences inevitably result from the determinants of our present-day life, including lack of exercise and an excess of food intake. The resulting negative factors on our health are high blood pressure, diabetes and obesity. Smoking and regular alcohol consumption is the icing on the cake for this dangerous trend.

    The Canadian biotechnology Company Cardiol Therapeutics focuses on researching and developing anti-inflammatory therapies to treat cardiovascular diseases. Its main product is a pharmaceutically produced ultra-pure, highly concentrated cannabidiol oral formulation called CardiolRx™️. The product is being targeted at reducing inflammation and fibrosis in the heart, specifically acute myocarditis and diastolic heart failure.

    An unfortunate combination occurs when simple flu-like infections and stress-related factors result in severe heart muscle inflammation because viral infections cause most inflammatory diseases of the heart. However, because many heart conditions do not manifest themselves until late in life, serious symptoms are often underestimated as age-related and ignored. Cardiol Therapeutics wants to set milestones in research here and is already in clinical phase II/III with its studies.

    The Company was recently able to raise another CAD 22 million, which means that the current research pipeline is fully financed. If successful, this could lead to a multiplication of the current market capitalization of CAD 130 million.

    CureVac - No safety concerns with new CVnCoV vaccine

    While several vaccines have now been available for several months, data continues to be collected for the approval of the vaccine from the Tuebingen-based biotech Company CureVac. It is still expected that the data will be available in June so that the rolling approval process with the European Medicines Agency (EMA) can be finalized.

    The reason for the long tests is the increasing changes in the currently known forms of the virus. A few months ago, the Coronavirus in its original form was dominant; however, the pandemic is now dominated by the much more dangerous mutations. CureVac's vaccine is thus naturally also being tested for its efficacy against precisely these mutations.

    But an initial interim result gives cause for optimism that CureVac will now receive approval in the near future. As the independent DSMB review board has now confirmed, there are no safety concerns about the active ingredient CVnCoV. Only the amount of data is still too small to make significant statements and thus prevents approval by the EMA.

    After the sharp rise of 190% in November 2020, the share is currently undergoing a correction. The high from December 2020 at EUR 120 has not yet been reached again. If the share price continues to move sideways, it will soon meet the short-term upward trend from March 2021. If the upward trend breaks, trouble threatens because the share will then head for the support at around EUR 73.

    Formycon - High expenditure on research and development

    The balance sheet of the Munich-based biotech Company Formycon still includes a lot of money for research and development. For 2020, the Company achieved sales of EUR 34.3 million, compared to EUR 33.2 million the year before. The operating loss increased from EUR 2.3 million to EUR 5.7 million in the process. The bottom line was a loss for the year of EUR 5.9 million, but this is within the Company's target range. Cash and cash equivalents are estimated at more than EUR 49 million.

    The Martinsried-based biotech Company is well aware that major advances in the fight against modern diseases do not fall from the sky but involve long testing and development phases. Formycon invested heavily in developing its own pipeline in the 2020 financial year in line with its growth strategy. In addition to the promising COVID-19 drug, FYB207, this primarily involved advancing the as yet unpublished and unpartnered biosimilar candidate FYB206.

    In vitro neutralization of SARS-CoV-2 variants by FYB207 shows that the drug is even more potent against the B.1.1.7 variant of the virus, which is considered to be particularly infectious, than against earlier variants. That is excellent news in the fight against the pandemic. The Formycon share has gone through a long consolidation at the EUR 60 mark. The price behavior of the last few days looks as if a new breakout is now imminent. The previous high of EUR 79.8 dates back to February 2021.

    NanoRepro - The air is out for now

    NanoRepro AG has made incredible progress since the pandemic emerged. A year ago, the share price was still between EUR 1 and EUR 3; in the meantime, the price hyped up to EUR 22.4. The euphoria resulted from large orders for COVID-19 tests that NanoRepro was able to land in quick succession. Initially, demand was so great that the Company could not adjust its logistics quickly enough to the incoming business.

    However, the tide has turned in the self-testing market. Currently, supermarkets are dominated by a price drop that is visible to all, and large chains even offer the tests free with your purchase. At the beginning of March, these tests were already out of stock when they were put on the shelves.

    Based on previous plans for B2B corona antigen rapid tests and the partnership with Viromed, NanoRepro expects sales of at least EUR 250 million this year but is making this dependent on the pandemic's political situation. The Company is currently working at full speed with a renowned German research institute on developing an antibody test that checks immunity after a Corona vaccination because the conventional antibody test cannot generally provide any information about the success of the vaccination.

    In recent interviews, CEO Lisa Jüngst leaves no doubt that the Company will continue to operate just as successfully without Corona. However, the current trend of the share shows a different picture. Strong profit-taking and high turnover pushed the share price down by a further 50% in the last 6 weeks alone, and it is currently already 75% off the top. However, if management's expectations materialize, NanoRepro is far too cheap with a P/E ratio of 2 to 3.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by Fabian Lorenz on November 24th, 2022 | 12:40 CET

    New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check

    • Mining
    • Commodities
    • Biotechnology
    • chemicals

    As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.

    Read

    Commented by Stefan Feulner on November 22nd, 2022 | 13:42 CET

    Favorable starting positions for Commerzbank, Desert Gold and BioNTech

    • Mining
    • Gold
    • Investments
    • Biotechnology

    The suspected downward pressure due to uncertainties in the economy and geopolitics has so far failed to materialize. Instead, the most important stock indices, such as DAX or Dow Jones, were able to leave their short-term downward trends and are sending signals for a further upward push. In addition to the stock market, the precious metals sector was also able to turn around. Here, in particular, entry opportunities beckon at a significantly reduced level with the chance of long-term, disproportionate price gains.

    Read

    Commented by Nico Popp on November 21st, 2022 | 12:11 CET

    Biotech - Hotter than ever: Catalyst Pharmaceuticals, BioNxt Solutions, Bayer

    • Biotechnology

    Biotechs have been providing answers to humanity's most pressing questions for years. Innovative companies are applying advanced methods to make a medical difference. The example of BioNTech is just one success story among many. While companies in the pharmaceutical sector are finding it increasingly difficult to come up with real innovations, biotechs often put all their eggs in one basket - and win. We present two biotech hopefuls and take a look at Bayer.

    Read